Amgen Presentations & Investor Relations material
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen. Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to and thank you for your assistance.
amgen.comAmgen presentations

AMGEN Investor Presentation 2020

Amgen

American Academy of Dermatology Investor Call

Amgen

Q1 16 Earnings Call

Amgen

AMG 160 Data at Esmo Virtual Congress 2020

Amgen

Q117 Earnings Call

Amgen

AMG 133 Program Update

Amgen

Q4 ’23 Earnings Call

Amgen

Amgen at Asco20 Virtual Scientific Program

Amgen

Tezepelumab: a Differentiated, First-in-class Investigational Therapy For a Broad Population With Severe Uncontrolled Asthma

Amgen

Amgen Q2 ’15 Earnings Call

Amgen

2021 Annual Meeting of Stockholders

Amgen

Amgen to Acquire Horizon Therapeutics

Amgen

Q1 ’15 Earnings Call

Amgen

Biosimilars

Amgen

Investor Presentation

Amgen

Repatha: Steps to Improve Affordability and Access for Patients with Cardiovascular Disease

Amgen

Amgen Q3 ’15 Earnings Call

Amgen

Amgen Sotorasib Data at Esmo Virtual Congress 2020

Amgen

AMGEN Q4 ’15 Earnings Call

Amgen

Q4 ’17 EARNINGS CALL

Amgen

Amg 510 Update From Esmo 2019

Amgen

Q3 ’16 Earnings Call

Amgen

Q2 ’16 Earnings Call

Amgen
Amgen Q1 ’23 Earnings Call

Amgen

2014 Business Review

Amgen

Q4 ’18 Earnings Call

Amgen

42 Nd Annual J.P. Morgan Healthcare Conference

Amgen

Amgen Q2 14 Earnings Call

Amgen

Investor Presentation

Amgen

Q3 19 Earnings Call

Amgen

Amgen 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

Amgen

Q1 19 Earnings Call

Amgen

36th Annual J.P. Morgan Healthcare Conference

Amgen

KHK4083 Collaboration with Kyowa Kirin Lumakras™ (Sotorasib) Approval

Amgen

Hematology / Oncology Update Esmo 2023

Amgen

Q1 21 Earnings Call

Amgen
Categories
Finance PresentationsTechnology PresentationsBanking PresentationsInformation Technology PresentationsOil and Energy PresentationsInternet PresentationsMining and Metals PresentationsCommunications PresentationsReal Estate PresentationsBiotechnology PresentationsAutomotive PresentationsMedical PresentationsRetail PresentationsEnergy Presentations